Want to stay in touch with the latest updates from Pharmaceutical Business review? That's easy! Just subscribe clicking the Follow button below, choose topics or keywords for filtering if you want to, and we send the news to your inbox, to your phone via push notifications or we put them on your personal page here on follow.it.
Reading your RSS feed has never been easier!
Website title: Pharmaceutical Business review
Is this your feed? Claim it!
The financing will support Adcendo’s ongoing advancement of its first-in-class and best-in-class ADC pipeline targeting cancers of high unmet medical need, including further clinical development of three main programmes.
Jeito Capital led the round, joined by new investors Vida Ventures, BPI France, and EIFO (Export and Investment Fund of Denmark).
Previous inve...
The acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer.
The therapy is anticipated to have a US Food and Drug Administration (FDA) investigational new drug (IND) application this year.
Based in Houston and founded in 2023, CrossBridge Bio develops a dual-payload antibody drug conjugate (ADC) te...
The approval makes Filspari the first and only FDA-approved medicine to treat FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney condition.
FSGS is a rare disease, and patients without nephrotic syndrome include a group consistent with kidney disease: improving global outcomes (KDIGO) guidelines for glomerular diseases.
Nephrotic syn...
The treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy.
The FDA has scheduled a decision date for 10 October 2026 under the Prescription Drug User Fee Act.
Ifinatamab deruxtecan is a specifically engineered B7-H3-directed DXd antibody drug conjugate (ADC), which was discovered by Daiichi...
The decision affects Replimune’s lead product candidate, which is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response.
During the IGNYTE trial, patients treated with RP1 plus nivolumab showed a 34% response rate and a median duration of 24.8 months, with a favourable safety profile.
Replimune contends these...